The global metabolism drugs market, by Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Small Molecule Drugs, and Others), by Application (Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 5,765.3 million in 2017, and is projected to exhibit a CAGR of 6.3% over the forecast period (2018 – 2026). 

Availability of wide number of therapies such as small molecule drugs and enzyme replacement therapy, increasing prevalence of metabolic diseases, and robust pipeline is expected to fuel growth of the metabolism drugs market. Manufacturers are actively working on developing new therapies for various metabolic diseases.

For instance, various pipeline products include NeoGAA GZ402666 (Sanofi) in phase 3, AT-982 in phase 3 (Audentes Therapeutics)), and BMN 701 in phase 2 (BioMarin Pharmaceutical, Inc.) clinical trial are also expected to create a meteoric growth in this market during the forecast period. Amicus Therapeutics was granted with orphan drug designation for its investigational combination drug therapy ATB200/AT2221, in November 2017. This drug is intended to cure Pompe disease (acid maltase deficiency or AMD). in March 2018, Shire plc entered into a preclinical research collaboration with NanoMedSyn— French biotech company—to develop enzyme replacement treatment for a lysosomal storage disorder based on NanoMedSyn’s synthetic derivative technology named AMFA. Lixte Biotechnology Holdings, Inc., has LB-201/LB-205 in the preclinical stage, JCR Pharmaceuticals Co. Ltd. filed for JR-051 in Japan in 2017, and has many other products in the pipeline for treatment of metabolic diseases. Moreover, manufacturers such as Pharming Group NV and Orphazyme ApS also have products in the pipeline for metabolic diseases.

Browse 34 Market Data Tables and 43 Figures spread through 167 Pages and in-depth TOC on Metabolism Drugs Market, by Therapy Type (Enzyme Replacement Therapy, Substrate Reduction Therapy, Small Molecule Drugs, and Others), by Application (Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism Disease, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026

To know the latest trends and insights prevalent in the Metabolism Drugs Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/metabolism-drugs-market-1955

Partnerships and collaboration from individual organizations for research and development of effective therapies is expected to boost growth of the metabolism drugs market. For instance, in 2014, Shire Plc announced collaboration with ArmaGen to develop AGT-182 drug for treatment of hunter syndrome. Moreover, in 2017, Research funded by the National Institute of Neurological Disorders and Stroke (NINDS) demonstrated that viral-delivered gene therapy can stop the buildup materials stored in the brain cells and improve memory and learning. High return on investments, health insurance coverage, and various reimbursement policies for such costly drugs are influencing pharmaceutical companies to invest in drug development. For instance, in 2015, Orphan Product Grants Program funded 18 new grant awards from 92 grant applications and provided funding and support to around 67 ongoing clinical study projects related to rare disease. Furthermore, initiatives from the governments of economies such as Sweden, the Netherlands, and South Korea that focus on approving guidelines for the reimbursement of individuals undergoing enzyme replacement therapy (ERT) are also expected to boost growth of the metabolic drugs market (as enzyme replacement being major therapies in the market) in the near future.

Key Takeaways of the Metabolism Drugs Market:

  • The global metabolism drugs market is expected to exhibit a CAGR of 3% over the forecast period (2018 – 2026), owing to partnerships and collaboration for drug development by leading manufacturers such as Shire Plc
  • Enzyme replacement therapies are expected to be the driving factor behind growth of the metabolism drugs market
  • North America is expected to dominant position in the metabolism drugs market over the forecast period due to active research and development activities by leading players in the region
  • Major players operating in the global metabolism drugs market include Merck & Co., Inc., Novartis AG, Amicus Therapeutics, AstraZeneca Plc, Boehringer Ingelheim, Shire Plc, Sanofi Genzyme, BioMarin Pharmaceutical, Inc., Horizon Pharma Plc, and GlaxoSmithKline Plc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner